[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100568225":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":30,"centralContacts":34,"locations":26,"responsibleParty":39,"collaborators":26,"id":41,"slug":42,"hasResults":43,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":26,"eligibilityCriteria":47,"healthyVolunteers":43,"sex":48,"minAge":49,"maxAge":50,"enrollmentInfo":51,"targetDuration":26,"studyType":54,"phases":55,"briefSummary":57,"conditions":58,"keywords":26,"overallStatus":60,"whyStopped":26,"lastUpdateSubmitDate":61,"lastUpdatePostDateStruct":62,"startDateStruct":65,"completionDateStruct":67,"leadSponsor":69,"locationsCount":26},{"fullName":5,"class":6},"Shanxi Bethune Hospital","OTHER",[8,14],{"label":9,"type":10,"description":11,"interventionNames":12},"Sugammadex group","EXPERIMENTAL","When T2 appeared, the sugammadex group was given 2mg\u002Fkg of sugammadex intravenously (adjusted body weight)",[13],"Drug: Sugammadex",{"label":15,"type":16,"description":17,"interventionNames":18},"Neostigmine group","ACTIVE_COMPARATOR","When T2 appeared, the neostigmine group was given 0.04mg\u002Fkg of neostigmine + 0.02mg\u002Fkg of atropine intravenously (adjusted body weight).",[19],"Drug: Neostigmine",[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Sugammadex","When T2 appeared, the sugammadex group was given 2mg\u002Fkg of sugammadex intravenously (adjusted body weight), the neostigmine group was given 0.04mg\u002Fkg of neostigmine + 0.02mg\u002Fkg of atropine intravenously (adjusted body weight).",[9],null,{"type":22,"name":28,"description":17,"armGroupLabels":29,"otherNames":26},"Neostigmine",[15],[31],{"name":32,"affiliation":5,"role":33},"Jian-Wen Zhang, MD","PRINCIPAL_INVESTIGATOR",[35],{"name":32,"role":36,"phone":37,"phoneExt":26,"email":38},"CONTACT","+86 13994299284","zjw030001@126.com",{"type":40,"investigatorFullName":26,"investigatorTitle":26,"investigatorAffiliation":26,"oldNameTitle":26,"oldOrganization":26},"SPONSOR","100568225","sugammadex-on-laparoscopic-bariatric-surgery-100568225",false,"NCT06678451","Sugammadex on Laparoscopic Bariatric Surgery","Effect of Sugammadex on Quality of Recovery Following Laparoscopic Bariatric Surgery","Inclusion Criteria:\n\n* Age 18-50 years\n* Body Mass Index (BMI) ≥ 40kg\u002Fm²\n* American Society of Anesthesiologists (ASA) grade I to III classification\n* NYHA cardiac function grade I - II\n\nExclusion Criteria:\n\n* Patients with neuromuscular disease or respiratory system disease\n* Patients with severe abnormal liver and renal function\n* Perioperative use of drugs known to interact with rocuronium\n* Patients with unstable mental illness or refusal to participate","ALL","18 Years","50 Years",{"count":52,"type":53},60,"ESTIMATED","INTERVENTIONAL",[56],"NA","Laparoscopic bariatric surgery has been recognized as the most effective treatment for obesity and related metabolic diseases. Because obesity patients often associated with sleep apnea syndrome or obesity hypoventilation syndrome, combined with the residual effect of muscle relaxants during the operation is easy to lead to respiratory obstruction and respiratory insufficiency, and hypoxemia and carbon dioxide retention are easy to occur after surgery, Post-extubation is prone to upper respiratory tract obstruction such as retrolingual fall, thus increase the risk of perioperative respiratory complications. Therefore, it is very important to achieve a rapid and effective antagonistic muscle relaxant effect, reduce the postoperative muscle relaxation residue, and maintain the patency of the patient's airway.\n\nCompared with the traditional cholinesterase inhibitor neostigmine, sugammadex is a specific antagonist of novel aminosteroid muscle blockers, which rapidly reverses moderate and deep neuromuscular block by combining with rocuronium or vecuronium 1:1,without compatibility with due to its no effect on muscarinic receptors or plasma cholinesterase. The absence of cholinergic and cardiovascular effects during awakening from anesthesia would be significant benefit for patients with cardiovascular or respiratory diseases.\n\nThe pharmacological effect of sugammadex is its ability to form a tight 1:1 complex with amino steroid neuromuscular blockers, which causes a lower plasma concentration of free neuromuscular blockers and promotes the transfer of neuromuscular blockers from the peripheral compartment (including the neuromuscular junction) to the plasma gradient. A meta-analysis by Vaghiri et al showed that reversal of neuromuscular block by sugammadex accelerated postoperative recovery of intestinal peristalsis in patients undergoing colorectal surgery compared with acetylcholinesterase inhibitors. Deljou et al confirmed that reversal of neuromuscular blockade with sugammadex shortened the time to first postoperative defecation in patients compared with neostigmine \u002F glononium bromide. The study will investigate the effect of sugammadex in patients undergoing laparoscopic bariatric surgery.",[59,23],"Laparoscopic Bariatric Surgery","NOT_YET_RECRUITING","2024-11-05",{"date":63,"type":64},"2024-11-07","ACTUAL",{"date":66,"type":53},"2024-12",{"date":68,"type":53},"2025-05",{"name":5,"class":6}]